Bruker @ smash 2021

The Role of NMR in the Pandemic

Webinar Overview

During this one-hour session, we will discuss how NMR is being used to fight COVID-19.

Monday 30 August 2021

07:30 PM CEST

Key Topics

  • Initiatives and successful stories from the COVID19-NMR group to determine RNA and protein structures of SAR-CoV-2 and to investigate druggability of those structures by small molecules
  • Long COVID and the development of new methods for the investigation of systemic metabolic effects of SARS-CoV-2.
  • Characterization and delivery of small molecules drugs, biologics, new modalities and vaccines.
  • Challenges, opportunities and next steps.


Harald Schwalbe

Harald Schwalbe (born March 26, 1966 in Frankfurt am Main ) is professor and Deputy Managing Director at the Center for Biomolecular Magnetic Resonance (BMRZ) at the Goethe University Frankfurt am Main. At the Institute for Organic Chemistry and Chemical Biology there, he heads the "Structural Chemistry and Biology / NMR Spectroscopy" department and gives lectures on organic chemistry and in the field of nuclear magnetic resonance spectroscopy . His research focus is on the application of NMR spectroscopy to investigate the building blocks of protein synthesis : DNA , RNA and proteins.

Dr. Oscar Millet

Principal Investigator CIC bioGUNE

Dr. Oscar Millet is the group leader of the Precision Medicine and Metabolism group of the CIC bioGUNE. His research focuses on the use of nuclear magnetic resonance (NMR) in the study of biologically relevant proteins and enzymes, paying special attention to the metabolic information that can be extracted from biological samples such as serum and urine. He has been awarded the Real Sociedad Española de Química prize (2004), the Spanish NMR group prize (2005), and the Innovation Award of the Basque Government (2018). He is the scientific founder of the spin-off Atlas Molecular Pharma and is the president of the Spanish Chemical Biology Group.

Markus Schade, MBA, PhD

Principle Scientist - AstraZeneca

Dr. Markus Schade, MBA, has worked for over 20 years in the pharmaceutical industry, including Biotech’s, such as Evotec, as well as Big Pharma’s, such as Pfizer and AstraZeneca. Presently Markus works as a Principle Scientist in the Oncology Chemistry Department of AstraZeneca in Cambridge, UK. Markus’ NMR research interests include fragment-based drug discovery (FBDD), analytical chemistry and 3D conformational analysis of synthetic small as well as mid-sized molecules, such as PROTACs, characterization of complex API formulations and automation of small molecule structure verification. Markus studied biochemistry at the University of Hannover, Germany, and the Massachusetts Institute of Technology, USA, and holds a Ph.D. in structural biology from the Free University of Berlin and a MBA from the Berlin School of Economics, Germany.